Compare Organon & Co. Common Stock (OGN) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs United Microelectronics Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while United Microelectronics Corp trades at $20.43 (market cap $55.52B). The key difference: United Microelectronics Corp is far larger — about 15.3× Organon & Co. Common Stock's market cap, and United Microelectronics Corp pays the higher dividend (1.79%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and United Microelectronics Corp for 42 Days on average.
| OGN | UMC | |
|---|---|---|
Market Cap | $3.62B | $55.52B |
Volume | 2,892,999 | 8,712,351 |
Sector | Health | Technology |
52-Week High | $13.81 | $28.02 |
52-Week Low | $5.70 | $7.02 |
Typical Hold Time | 0 Days | 42 Days |
Enterprise Value | $11.04B | $52.61B |
Dividend Yield | 0.58% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
UMC trades at $21.40, down 5.1% in the past 24 hours, with mixed technical signals showing a bearish moving average trend but oversold RSI conditions. Fundamentally, the company demonstrates strong profitability with 32.75% net income margin and has beaten earnings estimates for three consecutive quarters, though revenue growth remains modest at 2.3% year-over-year for 2025.
The stock presents a mixed outlook with strong earnings performance and attractive valuation metrics offset by slowing revenue growth and competitive pressures. Analyst sentiment leans cautious with a 'Hold' consensus, while technical indicators suggest potential near-term support around current levels given oversold conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
